The therapeutic landscape for recurrent or metastatic SCCHN has benefited from the introduction of only one novel treatment in the past several years, Erbitux in 2011. Although Erbitux has improved treatment for many recurrent or metastatic SCCHN patients, most patients still relapse and ultimately die of their disease.  Owing to the high levels of unmet need for more-efficacious and better-tolerated therapies, significant commercial opportunity remains.

The “Unmet Need” module provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need in recurrent or metastatic SCCHN. We analyze the commercial opportunities in this market and how emerging therapies may capitalize on these opportunities.


Related Reports

Squamous Cell Carcinoma of the Head and Neck | Current Treatment | Detailed, Expanded Analysis: Physician Insights (US)

Immune checkpoint inhibitors have transformed the treatment algorithm for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (

View Details

Squamous Cell Carcinoma of the Head and Neck | Current Treatment | Detailed, Expanded Analysis (US): Treatment Sequencing

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

View Details

Squamous Cell Carcinoma of the Head and Neck | Disease Landscape and Forecast | G7 | 2019

Market Outlook Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)...

View Details

Squamous Cell Carcinoma of the Head and Neck | Landscape & Forecast | Disease Landscape & Forecast

Market Outlook Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN

View Details